- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02449512
Somatosensory Evoked Potentials From the Lower Urinary Tract
Somatosensory Evoked Potentials From the Lower Urinary Tract in Individuals With Neurogenic Lower Urinary Tract Dysfunction as a Result of Spinal Cord Injury
Spinal cord injury and other systemic neurological diseases (Multiple Sclerosis, Parkinson's disease) affect the integrity of lower urinary tract (LUT) function, leading to neurogenic lower urinary tract dysfunction (NLUTD). The urodynamic investigation is the current "gold-standard" for evaluating LUT function. Nevertheless, the sensory situation of the LUT cannot be investigated objectively. Furthermore, the current classification of the severity of the NLUTD due to spinal cord injury (SCI) does not represent the sensory situation of the LUT. Additional investigations therefore need to be established for assessing the sensory situation of the LUT. Somatosensory evoked potentials (SEPs) are an established method for investigating the processing of sensory nervous activity. However, SEPs from the LUT of SCI individuals have not yet been investigated.
A novel technique, i.e. diffusion tensor imaging (DTI), allows to process magnetic resonance images (MRI) in order to visualize nerve fibers. Using DTI, the innervation of the bladder after SCI can be visualized. The structural presentation of bladder innervation will be compared with the functional results, i.e. the SEP of the LUT in SCI individuals.
The primary objective of the proposed study is to elicit and characterize (latency, amplitude) the somatosensory evoked potentials (SEPs) from the bladder in individuals suffering from neurogenic lower urinary tract dysfunction as a result of spinal cord injury.
Furthermore, the SEPs from the bladder will be compared with the SEPs from peripheral nerves (N. tibialis, N. pudendus, N. medianus).
Moreover, the latency and amplitude of the SEPs from the bladder of individuals with somato-sensory complete spinal cord injury will be compared with those from the bladder of individuals with somato-sensory incomplete spinal cord injury.
Finally, the structural innervation of the bladder after SCI will be compared with the remaining sensory function.
Study Overview
Status
Conditions
Study Type
Contacts and Locations
Study Locations
-
-
LU
-
Nottwil, LU, Switzerland, CH-6207
- Swiss Paraplegic Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Informed Consent as documented by signature
- Chronic SCI of a minimum of 1 year
- Aetiology of SCI: traumatic
Exclusion Criteria:
- Age < 18 years or > 70 years
- Aetiology of SCI: non-traumatic
- History of bleeding disorder
- History of chronic neuropathic pain
- Intravesical botulinum toxin injections < 12 months ago
- Bladder management using indwelling catheters (suprapubic, transurethral)
- Bladder augmentation
- Sacral deafferentation
- Sacral neuromodulation
- Acute, symptomatic urinary tract infection
- Pregnancy
- Urolithiasis
- Bladder cancer
- Exclusion criteria for MRI (cardiac pace maker, implanted metal etc.)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
|---|
|
complete
individuals with somato-sensory complete spinal cord injury
|
|
incomplete
individuals with somato-sensory incomplete spinal cord injury
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
occurrence of somatosensory evoked potentials from the bladder
Time Frame: within 1 week after enrollment into study
|
within 1 week after enrollment into study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
latency of somatosensory evoked potentials
Time Frame: within 1 week after enrollment into study
|
within 1 week after enrollment into study
|
|
peak-to-peak amplitude of somatosensory evoked potentials
Time Frame: within 1 week after enrollment into study
|
within 1 week after enrollment into study
|
|
nerve fiber density around bladder
Time Frame: within 1 week after enrollment into study
|
within 1 week after enrollment into study
|
|
fractional anisotropy of nerve fibers around bladder
Time Frame: within 1 week after enrollment into study
|
within 1 week after enrollment into study
|
|
apparent diffusion coefficient of nerve fibers around bladder
Time Frame: within 1 week after enrollment into study
|
within 1 week after enrollment into study
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
age
Time Frame: 1st day
|
1st day
|
|
|
gender
Time Frame: 1st day
|
1st day
|
|
|
severity of spinal cord injury
Time Frame: 1st day
|
American Association of Spinal Cord Injury Impairment Score
|
1st day
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jens Wöllner, Swiss Paraplegic Centre
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2014-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurogenic Lower Urinary Tract Dysfunction
-
Swiss Paraplegic Centre NottwilCompletedNeurogenic Lower Urinary Tract DysfunctionSwitzerland
-
Qilu Hospital of Shandong UniversityTongji Hospital; Shandong Provincial Hospital; Sun Yat-Sen Memorial Hospital... and other collaboratorsNot yet recruitingNeurogenic Lower Urinary Tract Dysfunction | Rechargeable Sacral Neuromodulation DeviceChina
-
Samsung Medical CenterCompletedNeurogenic Lower Urinary Tract DysfunctionKorea, Republic of
-
Novartis PharmaceuticalsTerminatedNeurogenic Urinary Bladder | Neurogenic Bladder Disorder | Neurogenic Dysfunction of the Urinary Bladder | Neurogenic Bladder, Uninhibited | Neurogenic Bladder, SpasticNetherlands, Germany, Switzerland
-
APOGEPHA Arzneimittel GmbHCompletedUrologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor FunctionRomania, Austria, Germany
-
Swiss Paraplegic Centre NottwilCompletedSpinal Cord Injury | Neurogenic Detrusor Overactivity | Neurogenic Lower Urinary Tract DysfunctionSwitzerland
-
Ulrich MehnertNCCR (National Center of Competence in Resaerch, Switzerland)CompletedHealthy | Neurogenic Bladder Dysfunction Nos | Nonneurogenic Neurogenic Bladder DysfunctionSwitzerland
-
Ankara City Hospital BilkentCompletedSpinal Cord Injury | Neurogenic Lower Urinary Tract DysfunctionTurkey (Türkiye)
-
Swiss Paraplegic Centre NottwilCompletedSpinal Cord Injury | Neurogenic Lower Urinary Tract DysfunctionSwitzerland
-
University of ZurichTerminatedNeurogenic Bladder DysfunctionSwitzerland